Anixa Biosciences (NASDAQ:ANIX) Announces Earnings Results

Anixa Biosciences (NASDAQ:ANIX) announced its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08), FiscalAI reports.

Anixa Biosciences Trading Down 2.4%

ANIX opened at $2.83 on Thursday. The stock’s 50 day simple moving average is $3.35 and its 200-day simple moving average is $2.99. The stock has a market cap of $96.28 million, a PE ratio of -9.13 and a beta of 0.51. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar purchased 21,000 shares of the business’s stock in a transaction on Friday, June 12th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $52,500.00. Following the completion of the purchase, the chief executive officer directly owned 630,812 shares in the company, valued at approximately $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 50,024 shares of company stock valued at $148,971 over the last three months. Corporate insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Anixa Biosciences by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after acquiring an additional 29,436 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Anixa Biosciences by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after purchasing an additional 7,271 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Anixa Biosciences by 1.7% in the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares in the last quarter. State Street Corp lifted its position in Anixa Biosciences by 32.0% during the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after buying an additional 38,540 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at approximately $355,000. 29.13% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on ANIX shares. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Weiss Ratings cut shares of Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Finally, HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.50.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.